The influence of 0.05% sodium polyanethol sulfonate on the growth of 24 strains of Neisseria meningitidis in broth medium was examined; several of the strains were markedly inhibited. A paper disk method was evolved for screening the sensitivity of various bacteria to sodium polyanethol sulfonate on solid medium; the highest sensitivity was observed in N. meningitidis and Neisseria gonorrhoeae. Zones of growth inhibition were also observed in a proportion of strains in certain species of gram-positive cocci, whereas all gram-negative bacilli were uniformly resistant. The implications of these observations for the routine use of sodium polyanethol sulfonate in blood culture media are discussed.
The influence of 0.05% sodium polyanethol sulfonate on the growth of 24 strains of Neisseria meningitidis in broth medium was examined; several of the strains were markedly inhibited. A paper disk method was evolved for screening the sensitivity of various bacteria to sodium polyanethol sulfonate on solid medium; the highest sensitivity was observed in N. meningitidis and Neisseria gonorrhoeae. Zones of growth inhibition were also observed in a proportion of strains in certain species of gram-positive cocci, whereas all gram-negative bacilli were uniformly resistant. The implications of these observations for the routine use of sodium polyanethol sulfonate in blood culture media are discussed.
Sodium polyanethol sulfonate (SPS; "Liquoid," Hoffman-La Roche) is added to fluid blood culture media in many laboratories in order to counteract the bacterial inhibitors of fresh human blood. In a prospective clinical study in this laboratory, a significant, favourable effect of 0.05% SPS upon the rate and speed of isolations of both gram-positive cocci and gram-negative bacilli was demonstrated (1) . In Neisseria meningitidis septicemias, however, an adverse effect was observed, in that the cultures showed better growth, earlier growth, or growth exclusively from the broth medium without SPS. This observation provided the impetus for the present investigation, in which the influence of 0.05% SPS on the growth of 24 N. meningitidis strains in broth medium has been examined. Also, a paper disk method has been evolved for screening the sensitivity of various bacteria to SPS.
MATERIALS AND METHODS
Twenty-one strains of N. meningitidis of various serological groups received from Kaptein W. Wilhelmsen og Frues Bacteriological Institute, Rikshospitalet, Oslo, and three strains isolated from clinical specimens in this laboratory were examined.
Broth cultivation experiments. A titration of the meningococci was performed in serum broth with and without 0.05'7. SPS, followed by plating onto chocolate agar plates (nutrient agar base produced in this laboratory and supplemented with 8% defibrinated, heated horse blood and 14% heat-inactivated horse serum) after 18 h of incubation. Nutrient broth as used in the blood culture work in this hospital was employed, with the addition of 5% horse serum inactivated at 56 C for 30 min. The broth media were distributed in tubes in amounts of 3 ml. (Table 1 , rows). In only three strains was the highest end point observed in broth with 0.05% SPS, and the difference was up to one whole dilution step only. In contrast to this, 12 strains showed the highest end point of growth in serum broth without SPS, and the differences in end point in these strains mounted up to five dilution steps. (Strains which in addition to a difference in end point also presented a quantitative difference in the last dilution step yielding growth from both tubes were plotted intermediate between two whole dilution steps (Table  1) . From this asymmetrical distribution of the colony formation pattems from serum broth with and without SPS, it is concluded that 0.05% SPS exerted an inhibitory effect on the growth of several of the strains tested in serum broth. The inhibitory effect was dependent on the number of organisms in the inoculum; the heaviest inocula employed were not inhibited. The serological groups of the strains examined are included in Table 1 hemolytic streptococci of group A both showed an incomplete inhibition in about half of the strains tested. All the remaining bacteria tested proved completely resistant, in that colonies of normal size were formed right up to the edge of the SPS paper disk. These included, among others, Staphylococcus aureus and the gramnegative bacilli. In addition to the material presented in Table 3 , a further 62 strains of S. aureus and an equal number of strains within Enterobacteriaceae were tested on PDM agar without blood added; all of the strains showed complete absence of any zone formation. DISCUSSION The broth cultivation experiments clearly showed that the growth of several of the N. meningitidis strains tested were inhibited by the presence of 0.05% SPS in the broth medium.
In 8 of the 24 strains, the difference in end point in broth with and without SPS exceeded one dilution step ( Table 1 ). The magnitude of the difference in end point is considered to reflect the SPS sensitivity of the strain tested in terms of the size of the largest inoculum inhibited. A strain-to-strain variation in SPS sensitivity is thus evident. No significant correlation between SPS sensitivity and serological group could be demonstrated. The method employed in the present study may be rather insensitive in detecting growth inhibition by SPS in broth; it is possible that other techniques may detect more strains in which only small numbers of organisms are inhibited. In clinical bacteremias low numbers of organisms are often present in the blood stream. On the basis of these considerations, the present findings are concluded to be in good accordance with the repressed growth of N meningitidis from clinical blood cultures earlier observed (1) . The results of the broth cultivation experiments also harmonize well with those of the SPS paper disk testings, in which N. meningitidis (and N. gonorrhoeae) showed the highest degree of growth inhibition of all the bacterial species examined. The inhibitory effect of 0.05%; SPS on the growth of N. meningitidis has apparently not been described in the literature before. Von Haebler and Miles reported that the growth of two strains of N. meningitidis were inhibited by 0.1% SPS, whereas 0.05% was noninhibitory (5).
Hoare (3) and Kocka et al. (4) demonstrated that the growth of anaerobic streptococci was inhibited by SPS in artifical fluid blood cultures. Graves et al. (2) , using a paper disk technique, found that the growth of Peptostreptococcus anaerobius was inhibited by SPS, whereas other anaerobic cocci grew in the presence of SPS. In the present study, 10 strains of anaerobic streptococci proved resistant in the SPS paper disk technique. The significance of this apparent discrepancy is uncertain. The correlation between the zone formation in the latter technique and the effect of SPS in fluid media is not known, apart from N. meningitidis (Table 1 ). The SPS paper disk method, however, is considered to reflect the relative sensitivity to SPS of various bacterial species when grown on solid media. The finding that the formation of zones of growth inhibition in the strains of N. gonorrhoeae examined was at least as pronounced as that in the meningococci (Table  2 ) raises the question whether the growth of N. gonorrhoeae may possibly also be inhibited by the addition of 0.05% SPS in the blood culture medium. This question cannot be answered without additional studies.
The fact that zones of growth inhibition in the SPS paper disk technique were observed in the Neisseriae and in a proportion of strains within certain species of gram-positive cocci, whereas all strains of gram-negative bacilli tested were completely negative, harmonizes well with our earlier finding that the growth-promoting effect of 0.05% SPS in broth medium for blood cultures was more pronounced in gram-negative bacteremias than in those caused by gram-positive cocci (1) .
These findings naturally lead to the conclusion that duplicate blood cultures with and without SPS should be used routinely. Alternative compounds, such as sodium amylosulfate (4), should be subjected to extensive clinical and laboratory trials.
